Pfizer posts Q1FY22 PAT of Rs. 199.91 Cr

The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.

Pfizer and BioNTech expects third dose clinical studies of COVID-19 vaccine in August

The companies anticipate clinical studies to begin in August, subject to regulatory approvals

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY

Pfizer registers Q4FY21net profit at Rs 100 Cr

Revenue from operations for the year ended March 31, 2021 is ?2,239 crore

Pfizer registers Q3FY21 PAT at Rs. 141.24 Cr

The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.

Earendil Labs bags $787m to supercharge AI-driven biologics pipeline

Capital infusion to accelerate Earendil’s R&D platform

Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline

Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law

Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future

India in the Changing Landscape of Life-Sciences Research & Development

Valneva and Serum Institute end chikungunya vaccine partnership

Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries

Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial